Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Perennial Allergic Rhinitis

In brief

This Phase II Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Patients With Perennial Allergic Rhinitis.

Key facts

Study ID

NCT07459452

Run by

Jemincare

People needed

135

Starts

2026-04-01

Expected to finish

2028-10-01

Last updated by the study team

2026-03-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult participants ≥18 years and ≤65 years of age at the time of signing the informed consent form (ICF).
• Physician-diagnosed PAR at screening, symptoms of allergic rhinitis present for a minimum of 2 years.
• Participants must have been on stable treatment with intranasal corticosteroids (INCS), with or without other background medications for at least four consecutive weeks before randomization, and rTNSS≥6 at screening.
• Within 1 year prior to screening or at screening, participants must have positive indoor allergen SPT and/or positive antigen-specific serum IgE to indoor allergens . Participants must have clinical symptoms associated with perennial allergen positivity (assessed by SPT) or positive serum antigen-specific IgE at study entry .
• A participant who has a known history of dermatographism or identified during the SPT may participate in this study with a positive serum antigen-specific IgE test.
• Participants who have concomitant asthma must use permitted regular asthma treatment during the study and have been stable in the 3 months prior to screening.
• Is willing and able to comply with daily eDiary.
• Participants must complete the eDiary during the baseline evaluation period (2 weeks prior to randomization) and meet the following criteria: (1) complete the eDiary for at least 4 days per week; and (2) rTNSS score ≥6 at randomization (average of Day-7 to Day-1).

You may not qualify if…

• Is currently on AIT subcutaneous immunotherapy or sublingual immunotherapy.
• Have received treatment with any rescue medication or adjustment to background therapy medications during the baseline evaluation period.
• Prior intolerance or inadequate response to omalizumab.
• Contraindications or hypersensitivity to antihistamines or intranasal corticosteroids, or history of anaphylaxis.
• Have a history of seasonal worsening of AR and if the seasonal worsening is expected during the 2-week baseline evaluation period and the 24-week double-blind induction period.
• Anticipates significant changes in their daily environmental exposure during the 2-week baseline evaluation period and the 24-week double-blind induction period.
• Has a history of nasal polyps or nasal polyps present at screening, moderate-to-severe nasal septum deviation, or rhinitis secondary to other causes.
• Has a known history of recurrent acute or chronic sinusitis.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.